Señales en vivo de RENE.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (5 feb 2024 @ 09:22):

Stats
Volumen de hoy	530.00
Volumen promedio	9 313.00
Capitalización de mercado	1.93M
EPS	£0 ( 2023-11-07 )
Próxima fecha de ganancias	( £0 ) 2024-05-22
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.380
ATR14	£0.290 (859.26%)

Volumen Correlación

Largo: 0.09 (neutral)

Corto: 0.00 (neutral)

Signal:(12.475) Neutral

ReNeuron Group PLC Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ReNeuron Group PLC Correlación - Moneda/Commodity

-0.11
( neutral )

-0.25
( neutral )

-0.47
( neutral )

-0.70
( moderate negative )

0.28
( neutral )

ReNeuron Group PLC Finanzas

Annual	2022
Ingresos:	£530 000
Beneficio Bruto:	£-3.93M (-742.08 %)
EPS:	£-0.0947

FY	2022
Ingresos:	£530 000
Beneficio Bruto:	£-3.93M (-742.08 %)
EPS:	£-0.0947

FY	2022
Ingresos:	£403 000
Beneficio Bruto:	£403 000 (100.00 %)
EPS:	£-0.170

FY	2021
Ingresos:	£257 000
Beneficio Bruto:	£0.00 (0.00 %)
EPS:	£-0.290

Financial Reports:

No articles found.

ReNeuron Group PLC

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.